Citations

Clear

3030 citation(s) found for "Susan, M".

Prognostic Value of Biomarkers in Heart Failure
Gerber, Yariv , Weston, Susan A., Killian, Jill M. , Redfield, Margaret M. , Roger, Véronique L. , Dunlay, Shannon M.

Mayo Clinic

Circulation: Heart Failure | July 29, 2009 | Volume: 2 | Issue: 5 | Pages: 393-400

10.1161/circheartfailure.109.849299 | PMID 19808368 Get It

Background— Mortality among patients with heart failure is high. Though individual biomarkers have been investigated to determine their value in mortality risk prediction, the role of a multimarker strategy requires further evaluation. Methods and Results— Olmsted County residents presenting with heart failure from July 2004 to September 2007 were recruited to undergo biomarker measurement. We investigated whether addition of C-reactive protein, B-type natriuretic peptide, and troponin T to a model including established risk indicators improved 1-year mortality risk prediction using the c statistic, integrated discrimination improvement, and net reclassification improvement. Among 593 participants, the mean age was 76.4 years, and 48% were men. After 1 year of follow-up, 122 (20.6%) participants had died. Patients with C-reactive protein (<11.8 mg/L), B-type natriuretic peptide (<350 pg/mL), and troponin T (≤0.01 ng/mL) less than the median had low 1-year mortality (3.3%), whereas those with 2 or 3 biomarkers greater than the median had markedly increased mortality (30.8% and 35.5%, respectively). The addition of 2 or more biomarkers to the model offered greater improvement in 1-year mortality risk prediction than use of a single biomarker. The combination of C-reactive protein and B-type natriuretic peptide resulted in an increase in the c statistic from 0.757 to 0.810 ( P <0.001), an integrated discrimination improvement gain of 7.1% ( P <0.001), and a net reclassification improvement of 22.1% ( P <0.001). Use of all 3 biomarkers offered no incremental gain (integrated discrimination improvement gain 0.7% versus C-reactive protein+B-type natriuretic peptide, P =0.065). Conclusions— Biomarkers improved 1-year mortality risk prediction beyond established indicators. The use of a 2-biomarker combination was superior to a single biomarker in risk prediction, though addition of a third biomarker conferred no added benefit.
Multicenter Evaluation of an Investigational Prostate Cancer Methylation Assay
Baden, Jonathan , Green, George , Painter, Jennifer M, Curtin, K., Markiewicz, Jadwiga, Jones, Jennifer, Astacio, Tara, Canning, Susan , Quijano, Jedidiah, Guinto, Wilson, Leibovich, Bradley C. , Nelson, Joel B., Vargo, Janet M., Wuxiong, Cao, Wang, Yixin

Mayo Clinic

Journal of Urology | July 22, 2009 | Volume: 182 | Issue: 3 | Pages: 1186-1193

10.1016/j.juro.2009.05.003 | PMID 19625061 Get It

Brief Report: Natural History of Individuals With Clinically Recognized Monoclonal B-Cell Lymphocytosis Compared With Patients With Rai 0 Chronic Lymphocytic Leukemia
Rabe, Kari G. , Call, Timothy G. , Maddocks, Kami J. , Jenkins, G. Douglas , Jelinek, Diane F., Morice, William G. , Boysen, Justin C. , Schwager, Susan M., Bowen, Deborah A., Hanson, Curtis A. , Shanafelt, Tait D. , Kay, Neil E. , Zent, Clive S. , Morice, William George , Slager, Susan L. , Chaffee, Kari G.

Mayo Clinic

Journal of Clinical Oncology | July 21, 2009 | Volume: 27 | Issue: 24 | Pages: 3959-3963

10.1200/jco.2008.21.2704 | PMID 19620484 Get It

Purpose The diagnosis of monoclonal B-cell lymphocytosis (MBL) is used to characterize patients with a circulating population of clonal B cells, a total B-cell count of less than 5 × 109/L, and no other features of a B-cell lymphoproliferative disorder including lymphadenopathy/organomegaly. The natural history of clinically identified MBL is unclear. The goal of this study was to explore the outcome of patients with MBL relative to that of individuals with Rai stage 0 chronic lymphocytic leukemia (CLL). Patients and Methods We used hematopathology records to identify a cohort of 631 patients with newly diagnosed MBL or Rai stage 0 CLL. Within this cohort, 302 patients had MBL (B-cell counts of 0.02 to 4.99 × 109/L); 94 patients had Rai stage 0 CLL with an absolute lymphocyte count (ALC) ≤ 10 × 109/L; and 219 patients had Rai stage 0 CLL with an ALC more than 10 × 109/L. Data on clinical outcome were abstracted from medical records. Results The percentage of MBL patients free of treatment at 1, 2, and 5 years was 99%, 98%, and 93%, respectively. B-cell count as a continuous variable (hazard ratio [HR] = 2.9, P = .04) and CD38 status (HR = 10.8, P = .006) predicted time to treatment (TTT) among MBL patients. The likelihood of treatment for MBL patients was lower (HR = 0.32, P = .04) than that of both Rai stage 0 CLL patients with an ALC less than 10 × 109/L (n = 94) and Rai stage 0 CLL patients with an ALC more than 10 × 109/L (n = 219; P = .0003). Conclusion Individuals with MBL identified in clinical practice have a low risk for progression at 5 years. Because B-cell count seems to relate to TTT as a continuous variable, additional studies are needed to determine what B-cell count should be used to distinguish between MBL and CLL.
Myasthenic syndrome due to defects in rapsyn
Milone, Margherita , Shen, Xin‐Ming , Selcen, Duygu , Ohno, Kinji , Brengman, Joan M., Iannaccone, Susan T. , Harper, Charles M., Engel, Andrew G.

Mayo Clinic

Neurology | July 20, 2009 | Volume: 73 | Issue: 3 | Pages: 228-235

10.1212/wnl.0b013e3181ae7cbc | PMID 19620612 Get It

Modification of Ovarian Cancer Risk by BRCA1/2 -Interacting Genes in a Multicenter Cohort of BRCA1/2 Mutation Carriers
Chuai, Shannon, Friebel, Tara M. , Panossian, Saarene, Spurdle, Amanda B. , Chenevix‐Trench, Georgia , kConFab, Pfeiler, Georg , Lynch, Henry T., Weitzel, Jeffrey N. , Narod, Steven A. , Rubinstein, Wendy S. , Olopade, Olufunmilayo I. , Blum, Joanne L. , Nathanson, Katherine L. , Daly, Mary B., Rebbeck, Timothy R. , Mitra, Nandita , Domchek, Susan M. , Wan, Fei , kConFab, Singer, Christian F. , Neuhausen, Susan L. , Garber, Judy E. , Isaacs, Claudine , Couch, Fergus J. , Tomlinson, Gail Elizabeth , Ganz, Patricia A. , Tung, Nadine , Greenberg, Roger A. , Spurdle, Amanda B , Weitzel, Jeffrey N , Olopade, Olufunmilayo I , Nathanson, Katherine L , Chenevix-Trench, Georgia

Mayo Clinic

Cancer Research | July 7, 2009 | Volume: 69 | Issue: 14 | Pages: 5801-5810

10.1158/0008-5472.can-09-0625 | PMID 19584272 Get It

Abstract Inherited BRCA1/2 mutations confer elevated ovarian cancer risk. Knowledge of factors that can improve ovarian cancer risk assessment in BRCA1/2 mutation carriers is important because no effective early detection for ovarian cancers exists. A cohort of 1,575 BRCA1 and 856 BRCA2 mutation carriers was used to evaluate haplotypes at ATM, BARD1, BRIP1, CTIP, MRE11, NBS1, RAD50, RAD51, and TOPBP1 in ovarian cancer risk. In BRCA1 carriers, no associations were observed with ATM, BARD1, CTIP, RAD50, RAD51, or TOPBP1. At BRIP1, an association was observed for one haplotype with a multiple testing corrected P (Pcorr) = 0.012, although no individual haplotype was significant. At MRE11, statistically significant associations were observed for one haplotype (Pcorr = 0.007). At NBS1, we observed a Pcorr = 0.024 for haplotypes. In BRCA2 carriers, no associations were observed with CTIP, NBS1, RAD50, or TOPBP1. Rare haplotypes at ATM (Pcorr = 0.044) and BARD1 (Pcorr = 0.012) were associated with ovarian cancer risk. At BRIP1, two common haplotypes were significantly associated with ovarian cancer risk (Pcorr = 0.011). At MRE11, we observed a significant haplotype association (Pcorr = 0.012), and at RAD51, one common haplotype was significantly associated with ovarian cancer risk (Pcorr = 0.026). Variants in genes that interact biologically withBRCA1 and/or BRCA2 may be associated with modified ovarian cancer risk in women who carry BRCA1/2 mutations. [Cancer Res 2009;69(14):5801–10]
Reply to R.S. Go
Nowakowski, Grzegorz S. , Schwager, Susan M., Shanafelt, Tait D. , Kay, Neil E.

Mayo Clinic

Journal of Clinical Oncology | July 7, 2009 | Volume: 27 | Issue: 22 | Pages: e45-e45

10.1200/jco.2009.23.8683 Get It

O4‐01‐03: Genome‐Wide Association Study (GWAS) of plasma Aß levels in the dalmatian islands of Vis and korcula
Allen, Mariet , Younkin, Linda H., Campbell, Susan, Morgan, Joanne , Hastie, Nicholas D. , Campbell, Harry, Younkin, Steven G., Wright, Alan F., Ansari, Morad , Hayward, Caroline , Vitart, Véronique , Huffman, Jennifer E. , Polašek, Ozren , Rudan, Igor

Mayo Clinic

Alzheimer's & Dementia | June 25, 2009 | Volume: 5 | Issue: 4S_Part_5 | Pages: No page available

10.1016/j.jalz.2009.05.515 Get It

O3‐01‐01: Comparing predictors of conversion: Data from the Alzheimer's Disease Neuroimaging Initiative
Landau, Susan , Madison, Cindee, Foster, Normal L., Reiman, Eric M. , Shaw, Leslie M. , Trojanowski, John Q. , Petersen, Ronald C. , Weiner, Michael W. , Jagust, William J. , Harvey, Danielle

Mayo Clinic

Alzheimer's & Dementia | June 25, 2009 | Volume: 5 | Issue: 4S_Part_4 | Pages: No page available

10.1016/j.jalz.2009.05.421 Get It

An Analytical Model of Traumatic Diffuse Brain Injury
Thibault, L. E., Margulies, Susan Sheps

Mayo Clinic

Journal of Biomechanical Engineering | June 12, 2009 | Volume: 111 | Issue: 3 | Pages: 241-249

10.1115/1.3168373 | PMID 2779190 Get It

Diffuse axonal injury (DAI) with prolonged coma has been produced in the primate using an impulsive, rotational acceleration of the head without impact. This pathophysiological entity has been studied subsequently from a biomechanics perspective using physical models of the skull-brain structure. Subjected to identical loading conditions as the primate, these physical models permit one to measure the deformation within the surrogate brain tissue as a function of the forces applied to the head. An analytical model designed to approximate these experiments has been developed in order to facilitate an analysis of the parameters influencing brain deformation. These three models together are directed toward the development of injury tolerance criteria based upon the shear strain magnitude experienced by the deep white matter of the brain. The analytical model geometry consists of a rigid, right-circular cylindrical shell filled with a Kelvin-Voigt viscoelastic material. Allowing no slip on the boundary, the shell is subjected to a sudden, distributed, axisymmetric, rotational load. A Fourier series representation of the load allows unrestricted load-time histories. The exact solution for the relative angular displacement (V) and the infinitesimal shear strain (ε) at any radial location in the viscoelastic material with respect to the shell was determined. The strain response for brain tissue (μ = 345 Poise, G = 1.38 × 104 Pa) was examined at the non-dimensional radial location R = 0.3. The size (1.8<R0<6.8 cm) and constitutive properties of the brain, and the magnitude, duration (2<TD<100 msec) and waveform (sine, square, triangle) of the applied load were varied independently; each contributed to the response of the tissue. Strain increased linearly with increasing magnitude of the applied load and exponentially with increasing brain size (where the exponent n was frequency-dependent). Peak angular acceleration (Θ¨p) and peak angular velocity (ΔΘ˙p) were defined as appropriate load descriptors. As ΔΘ˙p increased, strain rose rapidly and was independent of Θ¨p, then levelled off and was highly sensitive to Θ¨p.
Effectiveness of Placebo Therapy for Maintaining Masking in a Clinical Trial of Vergence/Accommodative Therapy
Kulp, Marjean Taylor , Mitchell, G. Lynn , Borsting, Eric , Scheiman, Mitchell , Rouse, Michael , Tamkins, Susanna M. , Reuter, Kathleen, Cotter, Susan A. , Mohney, Brian G. , Toole, Andrew J.

Mayo Clinic

Investigative Opthalmology & Visual Science | May 26, 2009 | Volume: 50 | Issue: 6 | Pages: 2560

10.1167/iovs.08-2693 | PMID 19151384 Get It